Alexander Arrow, MD, CFA
He began his career as a surgical resident at the UCLA Medical Center, but left clinical practice in 1996 to become a sell-side equity research analyst covering medical technology. He switched careers a second time in 2007 when he left Wall Street to become the Chief Financial Officer of Johnson & Johnson – backed interventional cardiology start-up company Arstasis, Inc. During his five years as CFO the company grew from 30 to 120 employees and took a product concept through a multi-center clinical trial and into 140 U.S. hospitals. He has an MD from Harvard Medical School, and a BA in Biophysics, magna cum laude, from Cornell University.
Chief Executive Officer
Dr. Arrow co-founded Corramed, Inc. in 2023 with Dr. Wilfrido Mojica. He has served in senior management roles or as a board member of medical device and biotechnology companies in the fields of interventional cardiology (Arstasis, Inc.), neuroscience (Circuit Therapeutics, Inc.), immuno-oncology (Neumedicines, Inc.), dentistry (Biolase, Inc.), otolaryngology (Zelegent, Inc.), hemostatic agents (Medcura, Inc.), neuro-active peptides (Protagenic Therapeutics, Inc.), spine surgery (Carlsmed, Inc.), solid organ transport (Paragonix Technologies Inc.), ophthalmology (Insightful Instruments, Inc.), and automation of drug discovery research tools (Strateos, Inc.).
Wilfrido Mojica, MD
He has become an advocate to bring awareness to the presence of dislodged tumor cells in biopsy procedures, and in developing methods to save and utilize all the diagnostic cellular components that are often unkowningly available, but routinely not taken advantage of, so that high value outcomes can be derived to the benefit of the patient and cancer research. He has authored journal articles on this topic that have appeared in the American Journal of Interventional Radiology, the Journal of Clinical Pathology, and other peer-review publications. He seeks to change the current paradigm of suboptimal specimens being received in the pathology laboratory for testing to one characterized by the receipt of quality specimens in resulting in quality testing out. He has an MD from the St. Louis University School of Medicine, an M.S. in Physiology from Georgetown University, and a B.S. in Biological Sciences from the University of California, Irvine. He completed his pathology residency in Anatomic and Clinical Pathology at the State University of New York at Buffalo, and a Fellowship in Surgical Oncologic Pathology at the Roswell Park Cancer Institute.
CHIEF TECHNOLOGY OFFCER
Dr. Mojica, a practicing pathologist, co-founded of Corramed, Inc. in 2023 with Alexander Arrow. He is the chief of pathology at the Niagara Falls Memorial Medical Center, a community-based hospital that serves an inner-city population in Niagara Falls, NY. He is also an Associate Professor at the University at Buffalo (SUNY) in the Department of Pathology and Anatomical Sciences where he is involved in education of both medical and dental students. He has been interested and studied specimen procurement strategies from the surgical and interventional radiology perspective for years and has been developing methodologies to improve their recovery for testing once received in the pathology laboratory.
Shannon J. McCall, MD
Scientific Advisory Board Member
Dr. McCall is an Associate Professor and the Vice Chair for Translational Research at the Department of Pathology of Duke University Medical Center. She is also the Director of the Duke Biospecimen Repository & Precision Pathology Center (Duke BRPC), a shared resource of the School of Medicine and the Duke Cancer Institute. She’s been a member of the Duke Cancer Institute since 2017. She is also the principal investigator (P.I.) for the National Cancer Institute's Cooperative Human Tissue Network Southern Division (12 states). Her areas of specialization include general gastroenterology, esophagus, stomach, colon, liver, and pancreatic tumors. Some of her published work contributed to the understanding of the unmet clinical need for the Corramedical Crow’s NestTM Biopsy Catchment System, in particular her seminal paper “Precision Pathology as Part of Precision Medicine: Are we Optimizing Patient’s Interests in Prioritizing Use of Limited Tissue Samples” Journal of Clinical Oncology Precision Oncology, 2019. She joined the Corramedical Scientific Advisory Board in January 2024.
Kenneth Pritzker, MD, FRCPC
Dr. Pritzker has pioneered writings on the implementation of cancer genomic and genetic tests. He serves as the CEO of SWAN Cytologics, and York Medtech Ventures, and as a Senior Advisor to Proteocyte Diagnostics, Inc., and RNA Diagnostics, Inc. Among his many peer-review publications, a review paper he wrote in 2019, Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care, Arch Pathol Lab Med. 2019;143:1399–1415 contributed to the inspiration for the mission of Corramedical, Inc. He joined the Corramedical Scientific Advisory Board in January 2024.
Scientific Advisory Board Member
Dr. Pritzker is a Professor Emeritus at the University of Toronto's Department of Laboratory Medicine and Pathobiology and Department of Surgery. From 1986 to 2008, Dr. Pritzker chaired the pathology and laboratory medicine department at Mount Sinai Hospital (MSH) in Toronto. His contributions to laboratory medicine, biomedical research, and hands-on experience implementing new diagnostic procedures have earned him recognition on a global scale. The laboratory at MSH rose to prominence as one of the world's leading organizations for cutting-edge lab services during his tenure there. As a companion diagnostic to colon cancer therapy, K-ras mutation testing, which today is considered standard-of-care, was introduced in Canada by Dr. Pritzker and his team.
David L. Waldman, MD, PhD, FSIR, FACR
Scientific Advisory Board Member
Dr. Waldman is the editor-in-chief of the American Journal of Interventional Radiology, one of the preeminent peer-review journals of the field, and the editor of one of the fundamental textbooks of interventional radiology, Elsevier’s Interventional Radiology Secrets. He is Professor & Chief Medical IT development officer, Associate VP of the Department of Imaging Sciences at the University of Rochester Medical Center, in Rochester, New York. Under Dr. Waldman’s leadership as a world-renowned teacher, scholar, academician, and administrator, the Section of Interventional Radiology has grown into national prominence. He has been on the faculty in the Department of Imaging Sciences since 1994. He is a Fellow of the Society of Interventional Radiology and Fellow of the American College of Radiology. He is also a consultant for Brighton Surgical Center, Rochester, New York and has an adjunct Clinical Faculty appointment at Rochester Institute of Technology, Rochester, New York. Dr. Waldman received the Lifetime Service Award from the American Board of Radiology; and Distinguished Service Award from the American College of Radiology. He is a Board Examiner for the American Board of Radiology in Interventional Radiology. He joined the Corramedical Scientific Advisory Board in March 2024.
David R. Braxton, MD
Scientific Advisory Board Member
Dr. Braxton is the Chief of Molecular Pathology Services at Hoag Memorial Hospital Presbyterian and the Hoag Family Cancer Institute in Newport Beach, California. He oversees the implementation of molecular diagnostic services and genomic profiling assays to guide personalized treatment strategies for cancer patients. He is known for advancing precision oncology initiatives at Hoag, one of the highest volume regional cancer centers in California. He is double-board certified in (1) Anatomic and Clinical Pathology, and (2) Molecular and Genetic Pathology. His clinical interests include the histological diagnosis of gastrointestinal, liver, and pancreatic disease as well as the application of molecular diagnostics in personalized medicine. He serves as Chair of the pathology working group, Precision Oncology Alliance, Caris Life Sciences. He joined the Corramedical Scientific Advisory Board in April 2024.
David B. Solit, MD
Scientific Advisory Board Member
David B. Solit, MD is a practicing medical oncologist, a laboratory scientist, and the Geoffrey Beene Chair for Cancer Research at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. As a member of the genitourinary oncology service, he specializes in the treatment of prostate and bladder cancers. He also serves as the director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology, and the Chief of MSKCC’s Molecular Medicine Service, in the Human Oncology & Pathogenesis Program. He leads a lab at MSKCC investigating when is it possible to inhibit an oncogenic pathway -- and thereby block tumor growth -- based on cell lineage and the specific mutations within the tumor.
Dr. Solit’s laboratory has been a leader in the development of selective inhibitors of the MAP kinase pathway, and defining mechanisms of resistance to RAF and MEK inhibitors. He pioneered the use of whole genome sequencing methods to identify occult predictors of drug response, work that serves as the basis for the NCI Extraordinary Responder Initiative. Via the Kravis Center for Molecular Oncology, Dr. Solit leads a multidisciplinary team of clinicians, geneticists, bioinformaticians and laboratory scientists whose mission is to integrate molecular and clinical information to develop therapies that are individualized to each patient’s cancer. He is a graduate of the University of Pennsylvania School of Medicine and completed a residency in Internal Medicine at Barnes-Jewish Hospital/Washington University in St. Louis. He joined the Corramedical Scientific Advisory Board in September 2024.
